register

News & Trends - Pharmaceuticals

Medicines Australia says new Strategic Agreement not to be finalised until after the Budget

Health Industry Hub | May 10, 2021 |

Pharma News: Delivering timely access to much-needed vaccines and innovative treatments for Australians is a priority for the Government, Medicines Australia, Industry and patients.

Medicines Australia has been working closely with the Minister and his Department since last year to develop a new 5-year Strategic Agreement to commence at the expiry of the current Agreement in July 2022, to deliver greater long-term certainty for both industry and Government. 

Medicines Australia has mutually agreed to continue discussions after the Budget to provide additional time for important but complex elements to be considered and finalised, as soon as possible.

Medicines Australia’s partnership with Government led to the announcement in October 2020 of the removal of the offset policy and the establishment New Medicines Funding Guarantee which will deliver new funding each year for the listing of the new medicines on the PBS, with approximately $2.8 billion in new funding expected to be committed over the next four years.

“We look forward to seeing the dividend of the New Medicines Funding Guarantee in next week’s Budget papers which will outline the investment in new PBS medicines listings since the last economic statement from Government,” Medicines Australia said in a statement.

“The Government and Industry’s immediate focus must remain the Covid-19 response and vaccine roll-out. Following next week’s Budget, we will work to finalise commitments in the new Agreement that prioritise tangible benefits for patients. 

“We look forward to agreeing further significant improvements in patient access to medicines and in particular, commitments to modernise Health Technology Assessment to keep pace with scientific breakthroughs and rapid advancements in medicines and technologies.”

Medicines Australia will continue to work with Government to deliver an Agreement that will meet the Australian community’s expectations and ensure that patients will be able to access new medicines and therapies when they need them.


News & Trends - Biotechnology

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

AusBiotech appoints new CEO: Former Sanofi corporate affairs and sustainability leader takes the helm

Health Industry Hub | April 23, 2024 |

Biotech News: AusBiotech, the nation’s leading industry body for the biotech sector, has named former leader at Sanofi, Rebekah Cassidy, […]

More


News & Trends - MedTech & Diagnostics

Federal government invests in Siemens Healthineers scanner to 'reduce wait times' for cancer diagnosis

Federal government invests in Siemens Healthineers scanner to ‘reduce wait times’ for cancer diagnosis

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: The Albanese Government is investing $12 million through the 2024–25 Budget, to purchase and install a […]

More


News & Trends - MedTech & Diagnostics

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Cardiac device benefits face more cuts, while technical services remain secure in the short term

Health Industry Hub | April 23, 2024 |

MedTech & Diagnostics News: Starting from July 2024, Cardiac Implantable Electronic Devices (CIED) listed on the Prescribed List (PL) will […]

More


News & Trends - Biotechnology

CSL's world-first gene therapy heads for MSAC assessment

CSL’s world-first gene therapy heads for MSAC evaluation

Health Industry Hub | April 23, 2024 |

Biotech News: CSL’s world-first gene therapy for haemophilia B is scheduled for consideration at the upcoming Medical Services Advisory Committee (MSAC) […]

More


This content is copyright protected. Please subscribe to gain access.